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ABSTRACT 
 
 Current neurological research indicates that the improper migration of neurons 
into subcortical white matter in humans may play a role in the etiology of schizophrenia, 
major depressive disorder, autism, and other psychological disorders. The purpose of this 
project was to isolate mRNA from both white and gray matter samples from mentally ill 
and healthy individuals in an effort to elucidate mRNA gene expression differences 
between white matter neurons and gray matter neurons, if any. These differences in gene 
expression may open new avenues of research and treatment in patients suffering from 
psychiatric disorders with genetic etiologies. 
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BACKGROUND 
 
 
Brain Morphology and Neuronal Function 
 The central nervous system (CNS) can be divided into three main groups of 
tissue: neurons, glial cells, and the extracellular matrix. Each group can vary considerably 
in both organization and morphology, but in general, neurons are the information-
processing cells of the CNS, glial cells maintain, support, and propagate the information-
processing power of the neurons, and the extracellular matrix provides additional support 
to the neurons and glial cells. Brain matter can also be divided into white and gray matter 
(Figure-1).  The diagram shows the distribution of white and gray matter within the 
human brain.  Neurons are found predominately within gray matter, while white matter is 
composed of mostly glial cells and myelinated axons (interstitial white matter neurons, 
IWMNs).   
 
 
 
 
 
 
 
 
Figure-1:  Diagram of the Positions of Brain White and Gray 
Matter.  Gray matter consists mostly of neurons, while white 
matter contains mostly glial cells and myelinated neurons. 
(Dugdale and Zieve, 2010) 
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Figure-2 shows a neuronal cross-section, delineating myelinated (blue) and non-
myelinated axons, as a key distinction between white and gray matter.   
 
 
 
 
 
 
 
 
 
Figure-2:  Diagram of a Neuron.  Note the difference between 
myelinated axons (blue) (found predominately in white matter) 
and non-myelinated axons (found predominately in gray matter).  
(Villareal, 2007) 
 
Psychiatric Disorders and Neuronal Density in Subcortical White Matter 
The complex interactions between white and gray matter has been the subject of 
much scientific research in the past twenty years. It has become apparent that 
morphological abnormalities in the white matter regions of the brain may have relevance 
to psychiatric disorders, especially in the subcortical region of the brain. Post-mortem 
psychiatric patients diagnosed with schizophrenia appear to show significantly increased 
densities of IWMNs within superficial or surface subcortical white matter (Yang et al., 
2011). Furthermore, these results have been duplicated time and again especially for a 
deficit subtype schizophrenia, although there are discrepancies between the studies in 
regards to the definitions of “superficial” and “deep” white matter where the IWMNs 
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were measured (Akbarian et al., 1993; Akbarian et al., 1996; Anderson et al., 1996; 
Eastwood and Harrison, 2003; Eastwood and Harrison, 2005; Kirkpatrick et al., 2003).  
Additionally, neurons within the grey matter of schizophrenics have displayed decreased 
dopamine, NMDA, and DARPP-32 receptor levels, although expression of these proteins 
within IWMNs remains unclear (Akbarian et al., 1996; Albert et al., 2002; Conner et al., 
2011). 
This type of white matter neuronal density analysis has been extended beyond just 
schizophrenia. Increased densities or altered distributions of white matter neurons both in 
“superficial” and “deep” white matter have been implicated as a causative factor in other 
complex neurological disorders, such as autism and bipolar disorder (Dupont et al, 1995; 
Connor et al, 2011).  In the case of bipolar disorder, MRI studies linked an increased 
volume of abnormal subcortical white matter with increased rates of adult onset cognitive 
impairments and mood-related disorders, while meta-analysis of similar studies confirms 
a volumetric difference in subcortical white matter, as well as variety of other volumetric 
differences in other brain regions in patients with bipolar disorder and major depressive 
disorder, although the differences vary between disorders (Dupont et al., 1995; Pillai et 
al., 2002; MacDonald et al., 2004; Arnone et al., 2009). In a perhaps more telling study, 
teenagers suffering from their first manic episode were shown to display axonal 
disorganization in white matter with diffusal tensor imaging, an MRI technique. The 
authors of the study suggest that this disorganization may be the result of a 
developmental deficiency (Adler et al., 2006). White matter microstructure abnormalities 
in individuals with bipolar disorder have been extremely well characterized through use 
of the diffusal tensor imaging technique.  In general, the studies confirm that the 
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microstructural elements of white matter in the subcortical and cortical areas are 
significantly altered in bipolar sufferers (Cannon et al., 1998; Beyer et al., 2005; 
McIntosh et al., 2005; Hulshoff et al., 2006; Schneider-Axmann et al., 2006; Yurgelun-
Todd et al., 2007; McIntosh et al., 2008; Rüsch et al., 2008; Sussmann et al., 2009). 
For autism, similar studies have linked increased subcortical white matter volume 
with autism and autism spectrum disorders.  In 2003, Herbert et al. performed MRI 
morphometric analysis on the brains of 17 male autistic children, and 15 male control 
brains, and found that there were significant increases in brain volume in male autistic 
children (Herbert et al., 2003). These general findings of young autistic children with 
increased or abnormal brain volumes, have been replicated in several other studies 
(McAlonan et al., 2004; Hazlett et al., 2005;  McAlonan et al., 2009; Chawarska et al., 
2011; Courchesne et al., 2011). In terms of cellular structure and white matter 
abnormalities, several studies have noted that ASD patients tend to have altered 
microstructure in the subcortical region, although conclusions vary from study to study 
(Lainhart, 2006; Cheng et al., 2010; Ameis et al., 2011; Vissers et al., 2011; Jeong et al., 
2011; Muller et al., 2011; Anderson et al., 2011).  It should be noted that these volume 
increases were not limited to subcortical or cortical regions of the brain; generally the 
autistic brains showed individual differences while still tending to be oversized. 
Interestingly, a similar study was conducted on adults living with ASD, but it was 
reported that white matter volume was significantly decreased rather than increased, 
adding an interesting side to the tissue regulation story of autism (Ecker et al., 2012). 
 While these studies are informative in terms of the physical location and structure 
of IWMNs within the brain, they do not address any genetic differences these cells may 
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possess, especially between normal and psychiatric patients.  Currently, there are two 
main theories regarding patient IWMNs.  The “tombstone” theory states that the 
increased IWMN density in psychiatric individuals represents the remnants of an earlier 
developmental problem that occurred during early infancy or childhood, but this density 
increase has little effect on brain transcription. Alternatively, the second theory states that 
IWMNs are transcriptionally active and alter the transcriptome of white matter within the 
brain, and this transcriptional alteration may have psychiatric or developmental 
consequences. This project will investigate whether these white matter neurons are in fact 
transcriptionally active, and if so, whether they are expressing various neuronal gene 
products related to psychiatric disorders.   White matter and gray matter neuronal tissue 
will be isolated from patient autopsy brains, and the up-regulation of specific target 
mRNAs will be monitored by RT-PCR and RNA-Seq whole transcriptome analysis.  The 
project will assay a variety of genes, carefully selected on the basis of Chip-Seq genome 
data provided by Cheung et al. (2010). 
 
Gene Selection 
Chip-Seq data was used to help identify potential genes for analysis in this 
project.  Figure-3 shows our lab’s previous Chip-Seq data (Cheung et al., 2010) for nine 
genes.  Age and gender-matched samples were tested in neuronal cells (green) and non-
neuronal cells (blue), for male (upper row) and female (lower row) samples, for the 
amount of methylation of H3Kme3, a general indicator of gene expression.  Overall, most 
of the 9 genes analyzed (SHANK3, GRIN1, GRIN2D, GLRA1, GLRA3, GABRG3, 
GABRG5, GABRA5, and GABRD) showed a noticeable increase in gene expression in 
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neuronal cells, indicating their potential relevance to this particular study, so were chosen 
for this project for analysis by RNA-Seq and qRT-PCR.   
 
Panel-A:  GRIN1 Expression 
 
 
Panel-B:  Shank3 Expression 
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Panel-C:  Grin2D Expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel-D:  GLRA1 Expression 
 
 
 
 
  
 12 
 
 
Panel-E:  GLRA3 Expression 
 
 
 
 
 
Panel-F:  GABRG3 Expression 
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Panel-G: GABRG5 Expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel-H:  GABRA5 Expression 
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Panel-I:  GABRD Expression 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure-3 (A-H): CHIP-Seq Data for Potential Genes of Interest. The above 
graphs show the relative levels of gene expression for the listed target gene in 
both neuronal (green) and  non-neuronal tissue (blue), for male (upper row) and 
female (lower row) samples, as assayed by H3Kme3 methylation activity.  Note 
that most assayed genes display neuronal expression, but little or no non-
neuronal expression.  Bars indicate levels of H3Kme3 modification, a marker of 
gene transcriptional activation. 
 
 
 
Target Gene Functions 
 Several genes were selected for assay by RNA-Seq and RT-PCR for their 
expression in neurons (discussed above), possible relevance to IWMNs in general, and to 
schizophrenia, autism, and major depressive disorders. These genes have functions 
relating either to synapse formation or inhibitory neurotransmitters. 
 
SHANK3 
 SHANK3, also known as ProSAP2, encodes a synaptic scaffolding protein that 
may serve as an organizer of other scaffolding proteins in the postsynaptic region (Baron 
et al., 2006). The shank3 protein has also been shown to form the postsynaptic density 
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complex with neurexins and neuroligins, which are cell-adhesion proteins located in 
glutamatergic synapses (Meyer et al., 2004).  Figure-4 shows a localization experiment 
for SHANK3.  The protein can be seen to localize to synaptic spines and postsynaptic 
densities in rat brains (Wendholt et al., 2006).  
 
 
 
 
 
 
 
Figure-4:  Neuronal Localization of Protein SHANK3.  Note 
the localization of the protein in synaptic spines and in post-
synaptic densities.  This protein has been linked to autism 
spectrum disorders.  (Wendholt et al., 2006) 
 
Later studies implicated SHANK3 with autism spectrum disorders (ASD) and 
other pervasive development disorders.  Moessner and associates (2007) determined 
through DNA sequencing and microarray analysis that SHANK3 variants were found in 
1% of 400 individuals with ASD, or their immediate families, but not in the control 
population. Combined with another study of large sample size (Durand et al., 2007), 
Moessner and colleagues found that SHANK3 deletions, duplications, and variants may 
be associated with 1% of all autism spectrum disorder patients (Moessner et al., 2007). 
Figure-5 shows a diagram of the SHANK3 gene and the positions mutated in the 
disorders. 
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Figure-5:  Diagram of the SHANK3 Gene and Sites Mutated 
in Autism Spectrum Disorders.  The mutation sites listed 
above the line represent those discovered by Moessner and 
colleagues (2007), while those shown below the line represent 
those found by Durand and colleagues (2007).  The SH3 box 
(gray) represents a Src homology-3 domain.  The PDZ box 
(white) represents a PDZ domain. The H box (black) represents a 
homer–binding site.  The C box represents a cortactin-binding 
site.  The SAM box represents a sterile α motif. (Moessner et al., 
2007) 
  
It should be noted that while SHANK3 mutations are “relatively” common (1%) in 
autism spectrum disorders, mutations in the genes encoding other proteins in the 
postsynaptic density complex (NGLN3, NGLN4, and NRXN1) have been found to be 
comparatively very rare. In the case of NGLN3, only one individual expressing a variant 
has ever been identified (Jamain et al., 2003).  Thus, currently it seems likely that 
SHANK3 is a better target for study than the other proteins forming the post-synaptic 
density complex. 
 
NMDA Receptor Subunits GRIN1 and GRIN2D 
 GRIN1 and GRIN2D are genes encoding N-Methyl D-Aspartate (NMDA) 
receptor subunits NR1 and NR2d.  The NMDA receptor is composed of a four-part 
assembly of two NR1 subunits and two subunits from the NR2A-2D subfamily or the 
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NR3 subfamily. NMDA-Rs are interesting in that they have two prerequisites before 
channeling ions across the cell membrane; 1) the neuron containing the receptor must 
depolarized, and 2) ligands glycine and glutamate must be bound to the receptor 
(Kleckner and Dingledine, 1988; Purves et al., 2008).  NMDA-Rs are thought to help 
balance and control interplay between neuronal excitation and inhibition, as well as play 
a role in long term potentiation and long term depression. Both of these neuronal actions 
are thought to play a role in memory formation and synaptic plasticity (Villman and 
Becker, 2007).  
With respect to schizophrenia (SCZ), NMDAR antagonists like PCP and 
ketamine often produce SCZ-type cognitive deficits, and individuals suffering from anti-
NR1 encephalitis suffer from SCZ-type deficits and memory loss (Krystal et al., 2002; 
Vincent and Bien, 2008; Dalmau et al., 2008; Amitai and Markou, 2010). A separate 
team of researchers based in Shanghai Jiao Tong University found a positive correlation 
between GRIN2B gene variants and schizophrenia in a Chinese population (Li and He, 
2006). More conclusively, mice that have been genetically engineered to only develop 
about 5% of the normal NR1 levels are phenotypically normal until adolescence, upon 
which time they display behavioral and social deficits that can be improved with 
treatment of anti-psychotic drugs haloperidol or clozapine (Ikeda et al., 1995; Sakamura 
et al., 1995; Ebralidze et al., 1996).  
Furthermore, NMDAR dysfunction and the failure to balance excitation/inhibition 
of neurons has become a leading theory regarding the neurobiological etiology of autism 
spectrum disorders (Polleux and Lauder, 2004). NMDAR function has also been 
implicated with bipolar disorder; two drugs, lithium and valproate, used to treat bipolar 
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disorder have been found to change NMDAR receptor function, implying a specific role 
in NMDAR function and bipolar disorder pathogenesis (Mundo et al., 2003; Hayden and 
Nurnberger, 2006). However, it should be noted that no GRIN1 or GRIN2D variants or 
truncated transcripts have ever been discovered; so it seems safe to conclude that any 
non-functional GRIN1 and GRIN2D is likely to be lethal (Forrest et al., 1994; Tarabeux et 
al., 2011).  Importantly, few studies have detailed whether the expression level of GRIN1 
or GRIN2D play a role in the etiology of schizophrenia or autism, or how expression 
levels of these genes change between IWMNs and gray matter neurons. One German 
study in particular links GRIN1 function to schizophrenia and lifelong depressive 
symptoms, showing that German schizophrenics who also suffered from lifelong 
depression displayed greatly increased rates (p-value < 0.01) of GRIN1 variants 
(Alexander et al., 2007). 
 
GLRA1 and GLRA3 
 GLRA1 and GLRA3 encode glycine receptor chloride channels that comprise a 
major part of the inhibitory system within the CNS (although the receptor also has a 
limited excitatory role during development) (Lynch, 2004). GLRA1-3 and GLRB1 exist in 
humans as homo-pentamers. Figure-6 shows a top view of the complete GLRA1 
pentamer and its ligand binding sites (shown as red in the figure). The glycine receptor 
channels are especially important for synaptogenesis, as glycine receptors have been 
shown to directly trigger rises in Ca
2+
, which are essential for the proper function of the 
synapse (Kirsch and Betz, 1998). 
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Figure-6:  Diagram of the Structure of the GLAR1 Protein.  
The protein exists in human brain as a pentamer.  The glycine 
binding sites are shown as red circles in the lower diagram. (Betz 
and Laube, 2006) 
 
In terms of pathology, GLRA3 has recently been theorized to be a causative factor 
in the development of autism spectrum disorders (Ramanathan et al., 2004). Ramanathan 
and colleagues reported the karyotyping and analysis of an autistic individual, age 11, 
who displayed the genetic deletion of one set of alleles for 33 genes, including the 
following genes, AMPA 2, GLRA3, GLRB, NPY1R and NPY5R, that are responsible for 
neurological growth and development. It should be noted that the ratio between active 
GLRA1-3 and GLRB protein changes as an individual develops; in infancy the GLRA2 
receptor protein and mRNA predominate, but by early adolescence the GLRA1 and GLRB 
protein have replaced the vast majority of the GLRA2 (Takahashi, 2005; Betz and Laube, 
2006).  Thus, it seems likely that proper management of glycine receptor expression is 
integral to the proper development and function of the adult brain. 
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GABA Receptor Subunits GABRG3, GABRG5, GABRA5, and GABRD 
 Finally, GABRG3, GABRG5, GABRA5, and GABRD are related genes that encode 
subunit proteins for GABAA, a well-studied hetero-pentameric receptor for gamma-
aminobutyric acid (GABA), the main inhibitory immune-transmitter in the CNS.  Like 
glycine receptors as described above, GABAA receptors bind their GABA ligand to 
transport Cl
-
 ions through the cell membrane to inhibit the firing of the neuron. GABAA 
receptors are widespread throughout the human body, although the distribution and 
subunit composition of the GABAA receptors varies depending on the tissue and stage of 
development. GABAA receptor density in the brain is greatest during infancy, and then 
diminishes as the individual develops (Chugani et al., 2001).  
GABAA receptor dysfunction is another highly promising area of autism research. 
SNP variants of GABRG3 and GABRA5 in particular have been determined to be genetic 
risk factors for autism, and are present at a much higher rate in autistic populations than 
in control populations (Menold et al., 2001). Even more telling, PET scans of autistic 
children using a radioactive GABA-R antagonist, flumazenil, revealed that autistic 
children possess significantly less GABA-binding sites in the limbic and hippocampal 
areas of the brain, while other important neurotransmitter receptors remain unaffected 
(Blatt et al., 2001). Furthermore, sophisticated statistical techniques performed by 
Ashley-Koch and associates revealed that while not statistically significant, GABRG3 
was linked to ASD; they go on to state that perhaps variants of GABRG3 are only genetic 
risk factors in some ASD subpopulations (Ashley-Koch et al., 2006). 
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GABAA receptor dysfunction has also been implicated with suicide victims and 
individuals suffering from major depressive disorder. A study was conducted by Merali 
and colleagues concerning mRNA expression levels of GABA receptors subunits, and 
determined that mRNA expression of all GABA receptor subunits were significantly 
diminished in the fronto-lateral cortex region of the brain (Merali et al., 2004).  Thus, it 
seems reasonable to assume that gene variants or changes in gene expression levels for 
GABA receptor subunits may have some role in complex psychiatric disorders. 
 
 
qRT-PCR and RNA-Seq 
 The main techniques used in this project to assay potential changes in specific 
mRNAs between white and gray matter neurons are quantitative RT-PCR and RNA 
sequencing whole transcriptome analysis (RNA-Seq).  For the RNA-Seq, RNA was 
purified from human brain tissue and sent for analysis at Eurofins, an international 
bioanalytics firm. Whole Transcriptome Shotgun Sequencing (WTSS) or a variant of the 
protocol was implemented at the company.  This technique allows for the analysis of all 
mRNA present within the sample cells. Generally, the process begins with the removal of 
ribosomal RNA, which normally accounts for nearly 90% of a cell’s transcriptome 
(Mortazavi et al., 2008). Further preparation of the RNA occurs, although the exact steps 
change given the needs of the particular sequencing project and the machines utilized. 
Next, the RNA is converted to DNA via the action of the enzyme reverse transcriptase, 
and polymerase chain reaction is performed, a four step process that duplicates DNA with 
each successive cycle. Further processing and statistical steps are usually required, but 
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these tend to vary given the differences between PCR machines and the desired analysis. 
Finally, the RNA is mapped and duplicative sequences removed, using a reference 
genome and the transcript data is assembled into a coherent picture. 
Quantitative RT-PCR (qRT-PCR) is a similar process, although it lacks the high-
throughput sequencing power of the WTSS described above.  Generally when using qRT-
PCR it is only possible to screen an RNA sample population for the presence of a few 
target mRNAs at time, although the general principle of using labeled primers and RT-
PCR cycles is similar to WTSS. In the case of qRT-PCR, random hexamer primers, or 
oligo-dT that hybridizes to mRNA poly(A) segment, are used with reverse transcriptase 
to produce cDNA, then the cDNA is amplified with gene-specific primers.  In the case of 
real time RT-PCR, the primers are fluorescently labeled, which allows the amplification 
process to be assayed throughout each cycle.  While PCR proceeds, only the genes that 
have been chosen to be amplified are duplicated.  In this particular project, a series of 
qPCR runs were made using primers specific for 1SHANK3, GRIN2D, and GABRG3.  
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PROJECT PURPOSE 
 
As stated in the Background section, there are currently two main theories about 
the role of interstitial white matter neurons (IWMN) in psychiatric disorders.  The two 
theories differ in whether IWMNs are transcriptionally active. The “tombstone” theory 
states that the increased IWMN density observed in some psychiatric individuals 
represents the remnants of an earlier developmental problem, but the increase does not 
alter the adult IWMN transciptome, as IWMNs are transcriptionally inactive.  The second 
theory states that IWMN neurons are transcriptionally active, so the increase in IWMNs 
in psychiatric disorders will alter the transcriptome of white matter and its function. This 
project will investigate whether IWMNs are transcriptionally active, and if so, whether 
they are expressing gene mRNAs previously shown to correlate with psychiatric 
disorders.  White matter and gray matter neuronal tissue will be isolated from patient 
autopsy brains, and the up-regulation of specific target mRNAs will be monitored by 
qRT-PCR and by RNA sequencing. 
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METHODS 
 
Brain Tissues 
Brain tissues were obtained by our lab through a variety of NIH grants.  Gray and 
white matter tissues were dissected by Dr. Yin Lin prior the beginning of this project, and 
stored at -80ºC until RNA purification. 
 
RNA Purification 
 RNA was isolated from white and gray matter human brain samples through use 
of an RNeasy Lipid Tissue Mini Kit (Qiagen). Aseptic technique was practiced, as well 
as precautionary safety regulations for the handling of human brain tissue.  RNA 
purification began with the thawing of approximately 100 mg of human brain samples on 
ice for approximately two minutes, before being homogenized in a 7 ml glass dounce 
homogenizer with 1.0 ml of QIAzol Lysis Reagent.  After the tissue was homogenized, it 
was transferred to an O-ring tube and allowed to incubate for five minutes at room 
temperature.  Then 200 µl of chloroform was added to the homogenized solution, and the 
solution was vortexed for 15 seconds. The solution was allowed to incubate for another 
two minutes at room temperature, before being placed on ice. This process was repeated 
until six samples had been processed. 
 Next, the samples were centrifuged for 15 minutes at 4ºC at 12,000g. After 
centrifugation, the samples had separated into an upper aqueous phase, and a thicker pink 
tissue phase at the bottom of the tube. The upper aqueous phase containing RNA was 
carefully transferred into a fresh Eppendorf tube, and one volume of 70% ethanol was 
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added to the solution. The tube was vortexed, and then added to the provided RNeasy 
spin-through column. The RNeasy column was immediately centrifuged at 11,000g for 
15 seconds, and the flow-through from the column was discarded.  Depending on the 
volume of the solution mixed above, another round of centrifugation with the remaining 
solution and the same column, was sometimes necessary to process the entire Eppendorf 
tube’s worth of solution. 
 At this point, another solution comprised of 10 µl of DNase1 stock solution and 
70 µl of Buffer RDD (provided by the RNeasy Lipid Tissue Mini Kit) was prepared. The 
80 µl prepared solution was then pipetted directly into the center of the flow-through 
column membrane. The flow-through column was then allowed to incubate for another 
15 minutes at room temperature. After this period of incubation, 350 µl of RW1 buffer 
was added to the center of the column membrane, and the column was centrifuged at 
11,000g for 15 seconds.  Next, 500 µl of Buffer RPE was added to column, and was 
centrifuged for another 15 seconds.  Finally, another 500 µl of Buffer RPE was added to 
the column, and centrifuged for 2 minutes. The column was then placed in a fresh, 
RNAse-free Eppendorf tube, while the flow-through and the original tube were 
discarded.  Then 30 µl of RNAse free water was added to the membrane of the column, 
and the column was centrifuged at 11,000g for 1 minute to elute the RNA from the 
column membrane into solution. 
 Each sample was tested for RNA concentration using a NanoDrop-1000 
Spectrophotometer, and was then stored at -80ºC until needed.  
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RNA-Seq and qRT-PCR 
After the full range of brain tissue samples had been processed, around 30 µl of 
each purified RNA solution was sent to a third-party RNA sequencing corporation to 
fully process using a proprietary WTSS method.  Additionally, a smaller set of samples 
had been sent for processing slightly earlier in the year, in order to get an idea of what to 
expect from the larger body of samples. 
While the results of the RNAseq are still being processed at the time this report 
was written, quantitative RT-PCR was used to provide a secondary set of results that 
could be used as an additional resource.  Primers for SHANK3, GRIN1, GRIN2D, GLRA1, 
GLRA3, GABRG3, GABRG5, GABRA5, and GABRD were designed and tested for 
efficacy via a series of standard curve experiments in an Agilent 7500 RT-PCR machine. 
In order to test the primers for efficacy, a protocol was developed where each primer was 
tested against various dilutions of template cDNA, or against a random sequence of 
nucleotides. Template cDNAs were synthesized by Invitrogen based on the RNA we sent 
them.  Several types of random hexamers were mixed to provide a random template 
mixture for the reverse transcriptase reaction. This mixture was then used in conjunction 
with the primers to determine the primer’s efficiency and specificity. 
Each 96-well plate used to test these primers was prepared in the following 
manner.  First, a plate map of the primers to be tested was developed, so that each primer 
would be tested in quadruplicate with ½ dilution cDNA template, ¼ dilution cDNA 
template, and 1/8 dilution cDNA template. Secondly, an empty 96-well plate was placed 
on ice, as well as the set of forward and reverse primers to be tested. At this point, eight 
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master mixes containing 31.2 µl of RNAse-free water, 260 µl of KAPA SYBR Fast 
qPCR buffer, 8 µl of combined forward and reverse primer for each gene, 10.4 µl of 
ROX low buffer, and finally 10.4 µl of appropriately diluted template cDNA were added 
to each tube of master mix. Each master mix was pipetted into the appropriate wells, 
before the qPCR process was initiated on the Agilent 7500 RT-PCR machine.  
Of the nine primer sets designed, only the primers for SHANK3, GRIN2D, and 
GRIN1 displayed acceptable levels of specificity. From this point, brain samples were age 
and gender matched as to minimize confounding factors so that two pairs of gray and 
white matter samples from each disease individual, and two pairs of gray and white 
matter samples from control individuals were placed on each plate to analyze. qRT-PCR 
analysis was performed on each purified RNA brain tissue sample for each of the three 
targets, as well as the housekeeping ribosomal gene 18S as a reference. 
After qRT-PCR analysis had been completed, statistical analysis was performed 
on the raw data produced by each qRT-PCR run, in order to determine the relative level 
of expression for each gene for each tissue sample, as well as illuminate any significant 
differences in gene expression between the sub-groups tested (Control, SCZ, Autism, 
BPD, and MDD brain samples). 
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RESULTS 
 
 
 Epigenetic analysis of white matter neurons may reveal gene expression 
differences in individuals suffering from schizophrenia, autism, and other psychiatric 
disorders, especially in those genes previously shown to be associated with psychiatric 
disorders.  In this project, several genes were selected for qRT-PCR analysis on the basis 
of their strong neuronal gene expression based on our lab’s previous Chip-seq data 
(Cheung et al., 2010), and based on their previous association with psychiatric disorders.  
Brain samples were obtained for autopsy patients for schizophrenia, autism, spectrum 
disorders, etc.  RNA was isolated from white matter and gray matter neurons, and was 
sent to Eurofins for RNA-Seq third-party analysis.  The samples were tested for RIN 
values using the Agilent 2100 Bioanalyzer, a microfluidics-based analysis device that 
uses very small volumes of RNA solution to determine RNA integrity.   
A subset of the original 9 gene candidates was selected for analysis by qRT-PCR 
in a 96-well format.  Figure-7 shows example qRT-PCR data for 18S rRNA (green and 
purple curves, left panel, left side), and for mRNAs for SHANK3, GABRD, and GRIN1 
(left panel, right side).  As the cycle numbers increase (x-axis), the amplicon levels rise.  
Note that the 18S amplicons appear early (cycles 8-16), as is typical for a high abundance 
RNA template.  In the melt curve (right panel), note the tight peaks indicating a narrow 
range of temperatures (X-axis) that successfully amplify this specific gene with these 
primers; no amplicons appear outside the annealing range of this set of primers.  Not all 
of the samples in the wells exhibited melt curves of this high caliber, so any 
underperforming primers were excluded from further data analysis. 
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Figure-7:  Example of Real Time qRT-PCR Data and Accompanying Melt 
Curves.  The left panel denotes an amplification plot for cycles 1-40 (X-axis) 
relative to amplicon abundance (Y-axis), obtained from a 96-well plate with 
quadruplicate samples.  Shown are curves for the relative expression of 18S 
rRNA (green and pink lines rising from the interference on the left side of the 
panel).  Note that the 18S amplicons come up early as expected for a high 
abundance RNA.  The right half of the panel shows the amplicons for mRNAs 
SHANK3, GABRD, and GRIN1.  The right panel shows several melting curves 
for the SHANK3 primers.  The X-axis shows the melting temperature tested, and 
the Y-axis represents amplicon formation.  Note the tight specific amplification 
obtained from this set of primers, as no amplicons formed outside the main 
annealing temperature for this set of primers. 
 
 
 Based on the melting temperature curves for nine genes, the RT-PCR reactions 
for mRNAs for SHANK3, GRIN1, and GABRD were selected for further analysis.  After 
each 96-well plate of qRT-PCR had been performed, all of the data from acceptable 
primers were entered into an Excel spreadsheet to determine statistical significance 
(Figure-8).  Each plot shows the data for a particular mRNA, for gray matter or white 
matter neurons, for control brains, schizophrenic brains, major depressive disorder brains, 
and autistic brains.  The Y-axis denotes 1/∆Cycle Threshold, a measure of the mRNA 
abundance, i.e. at which cycle does the amplicon reach 50% maximal amplification. 
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Figure-8: Normalized Gene Expression Data for SHANK3, 
GRIN1, and GABRD. Each graph displays a gene of interest, 
comparing its expression between control and different disease 
sub-groups, for gray and white matter neurons. The Y-axis 
denotes 1/∆Cycle Threshold, a measure of the mRNA 
abundance.  No difference was seen between the groups in this 
particular analysis. 
 
 Note that for this particular analysis, no strong difference was observed between 
the control samples and the disease samples for all genes, the calculated p-values for the 
complete set of data (not shown) indicated no statistically relevant differences. 
The results of this first analysis were confusing since previous data had indicated 
that GRIN1 expression is much lower in white matter tissue, so a second analysis was 
performed.  In the repeat analysis, brain samples with RIN values lower than 6.0 were 
removed (Figure-9).  RIN values represent the integrity of the RNA; RIN values less 
than 6.0 indicate that a sample has been significantly degraded, so that sample is perhaps 
not the best to use for analysis.  This second more restrictive analysis, found that GRIN1 
expression for all brain samples was significantly lower (p=0.0545) in white matter 
neurons.  The only other potentially significant finding (p=0.086) was that GRIN1 may 
be expressed at significantly higher levels for white versus gray matter neurons in Major 
Depressive Disorder brains. 
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Figure-9: Analysis of RIN > 6.0 Intact RNA Samples.  The 
CT averages expressed in ratio format are shown in the above 
table, while the T-test’s for each group are displayed in the lower 
panel. Note the two yellow highlighted boxes for GRIN1 
expression are near significance. 
  
Ratios SHANK3 (dCT) GRIN1 (dCT) GABRD (dCT)
Ratio (Gray:White) 1.030 1.132 1.003
Ratio Control (Gray:White) 1.056 1.125 0.924
Ratio Schizophrenia (Gray:White)1.618 N/A 1.222
Ratio MDD (Gray:White) 0.915 1.139 1.061
Ratio Autism (Gray:White) 0.961 N/A 0.822
T Tests SHANK3 GRIN1 GABRD
All Samples (Gray:White) 0.7353 0.0545 0.9793
Control T-Test (Gray:White) 0.7267 0.4123 0.7424
Schizo. T-Test (Gray:White) N/A N/A 0.3324
MDD T-Test (Gray:White) 0.5462 0.0863 0.5919
Autism T-Test (Gray:White) N/A N/A N/A
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DISCUSSION 
 
 The results of this project provided RT-PCR data for SHANK3, GRIN1, and 
GABRD, and indicate that GRIN1 mRNA expression may be significantly higher than 
normal in the white matter neurons in individuals with Major Depressive Disorder 
(MDD) versus normal brains. This gene may play a role in the etiology of the disorder.  
Previous research has not linked GRIN1 expression and MDD in patients, although one 
study (Alexander et al., 2007) did link GRIN1 variants to German schizophrenics who 
also suffered from lifelong depression. It should be noted that the vast majority of studies 
involving GRIN1 and mood disorders focus on Bipolar Disorder (Mundo et al., 2003; 
Hayden and Nurnberger, 2006), although it is possible that some of the same mood 
dysregulation problems affect both BPD and MDD sufferers.  
 Over the course of the project, several difficulties were overcome, mostly in the 
form of primer specificity. Only one third of the RT-PCR primers were found to be of 
acceptable quality after an arduous primer testing process. After this initial primer testing 
phase was completed, extensive real time RT-PCR analysis was performed.  
Unfortunately many of the same primer specificity issues were still present, and some 
samples were not able to be included in the final data analysis.  
 In the future, valid primer sets could be designed and tested for the remaining six 
genes of interest: GRIN2D, GLRA1, GLRA3, GABRG3, GABRG5, and GABRA5,   as 
described in the Background section. And the analysis could be extended to other 
candidate genes.  Given that a near-to-significant result was obtained with the limited 
analysis performed, it seems likely that other significant gene expression differences 
between gray and white matter neurons could be discovered in patients suffering from 
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psychiatric disorders, and these differences could be used to correct the defects in patient 
brains using gene therapy. 
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